Ayesha Dhillon-LaBrooy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ayesha Dhillon-LaBrooy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Tim Sparwasser
Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
2 shared publications - Beate Weidenthaler-Barth
Johannes Gutenberg University Mainz
1 shared publication - Eshraq Tantawy
Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes University Gutenberg, Mainz, Germany
1 shared publication - Fatima Boukhallouk
Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes University Gutenberg, Mainz, Germany
1 shared publication - Francesca Rampoldi
Institute of Medical Microbiology and Hygiene, University Medical Center of the Johannes University Gutenberg, Mainz, Germany
1 shared publication - Kathrin Luise Braband
Institute of Immunology, University Medical Center Mainz, Mainz, Germany
1 shared publication
Latest Publications
- Open Access
- 30 November 2023
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (3) , 235-248
The evolutionary tug-of-war of macrophage metabolism during bacterial infection
- 30 November 2023
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 35 (3) , 235-248
Open AccessThe evolutionary tug-of-war of macrophage metabolism during bacterial infection
- 12 October 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (4) , 844-854.e2
Inhibition of Mitochondrial Translation Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation by Targeting Vγ4+ γδ T Cells
- 12 October 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (4) , 844-854.e2
Inhibition of Mitochondrial Translation Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation by Targeting Vγ4+ γδ T Cells